Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

DPx buys its way into U.S. biologics with Gallus acquisition

DPx, the result of a $2.6 billion merger of Patheon and DSM Pharmaceutical Products, has acquired U.S. contract manufacturer Gallus BioPharmaceuticals.

Synexus snags another South African site and widens its footprint

Patient-recruitment specialist Synexus has expanded its presence in South Africa, buying up another trial site in the country as it touts a growing list of clients.

Cenix lands an early-phase deal with BASF's Metanomics

German CRO Cenix BioScience has signed a deal with a BASF subsidiary to help ferret out new biomarkers, focusing on the growing field of metabolomics.

CRO Onyx signs up to help CRUK handle cancer R&D

Cancer Research UK has enlisted contract drugmaker Onyx Scientific to pitch in on some of its early research projects, handling development and manufacturing for clinical trials.

PRA sets sights on a new PA hub

With months of dealmaking and mergers under its belt, CRO PRA Health Sciences is consolidating some of its outposts, constructing a new facility that will eventually house more than 850 employees.

Catalent lends its weight to an armed-antibody cancer candidate

Drug developer Catalent is teaming up with biomarker outfit Minomic International to get a new prostate cancer treatment into the clinic, tapping its expertise in crafting targeted oncology treatments.

Recipharm buys into Italy with $165M CMO deal

Swedish contract developer Recipharm is looking to expand its share of the European manufacturing market, trading $164.5 million for Italy's Corvette Pharmaceutical Services.

Quintiles and Illumina look to jump-start cancer R&D with genomics sweepstakes

Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.

CRO PharPoint signs up to get Otologic's hearing drug into the clinic

Biotech Otologic Pharmaceuticals has chosen North Carolina's PharPoint Research to run an early trial of its lead candidate, a treatment for hearing loss.

Parexel: Biotech's boom pays dividends for CROs

Like most CROs, Parexel International relies on Big Pharma for most of its service revenue. But the recent explosion in biotech IPOs and venture capital deals has put a lot of money in the hands of small drugmakers, and that's changing the approach for the industry's largest contractors, a company exec said.